Previous 10 | Next 10 |
Shares of Kodiak Sciences (NASDAQ: KOD) were jumping 17.3% higher as of 11:16 a.m. EST on Wednesday following the drugmaker's announcement after the market closed Tuesday of the specific pricing of a public stock offering. Kodiak plans to sell 6 million shares at a price of $46 per share -- ...
Schmitt Industries (NASDAQ: SMIT ) +13% on $2M stock repurchase plan . More news on: Schmitt Industries, Inc., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Stocks on the move, Read more ...
Kodiak Sciences (NASDAQ: KOD ) has priced its public offering of 6M common shares at $46.00 per share, for expected gross proceeds of ~$276M. More news on: Kodiak Sciences Inc., Healthcare stocks news, Stocks on the move, Read more ...
PALO ALTO, Calif. , Dec. 3, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,0...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of ...
Gainers: Kodiak Sciences (NASDAQ: KOD ) +70% . More news on: Kodiak Sciences Inc., ASLAN Pharmaceuticals Limited, Cortexyme, Inc., Stocks on the move, Read more ...
Shares of Kodiak Sciences (NASDAQ: KOD) were skyrocketing 85.8% higher as of 10:41 a.m. EST on Monday after rising as much as 146.5% earlier in the day. This huge jump was spurred by Kodiak's announcement that it was selling a capped 4.5% royalty right on potential global net sales of experi...
Kodiak Sciences (NASDAQ: KOD ) +6.6% in pre market as the Company agrees to sell a capped 4.5% royalty right on global net sales of KSI-301 to Baker Bros. Advisors, for $225M More news on: Kodiak Sciences Inc., Healthcare stocks news, Read more ...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Evercore ISI Heal...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million . KSI-301 is Kodiak's inve...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth...